A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.
Experimental Drug Acquiring Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for source information, while also receiving discount codes.
Active Trade on Social Networks
Separately, a robust market exists on Telegram, where groups with numerous of participants share “before and after” photos, administration instructions and claims of rapid UK delivery. Sellers promote the drug there before redirecting customers to WhatsApp for purchases.
Understanding Retatrutide
Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist patients lose up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.
Healthcare Professionals Express Concerns
Nevertheless, doctors and pharmacists have warned that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals injecting products of uncertain source.
Several professionals said the demand for retatrutide could be connected to the increasing price of licensed slimming treatments such as Mounjaro.
Regulatory Position and Implementation
Selling the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several influencers attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and supply can still violate pharmaceutical, advertising, and customer regulations, potentially leading to penalties, prosecution or imprisonment.
Service Reaction and Content Elimination
Based on the social media company, the platform has removed problematic material and banned related keywords and search suggestions. The company stated it was dedicated to keeping the service secure and allocating resources in strengthening compliance measures.
Online Trading Activities
Research also discovered communities with up to 9,000 members selling retatrutide using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately brings up channels with thousands of members, filled with photos of slimming results, positive reviews and detailed guides for mixing or injecting at home.
Within moments of joining one community, a vendor shared WhatsApp details, where most purchases occur. The vendor sent an guidebook and guaranteed shipping within 48 hours. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about weight, health issues or past usage.
Product Information and Costs
Within these groups, posts display black plastic packages with Royal Mail labels, claiming to include new batches. One message read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, mixed at home with sterile water, or pre-filled pens typically sold at 160 pounds for 20mg. When asked how long a pen should last, sellers give contradictory responses ranging from a few weeks to “depends on your body”.
Service Oversight and Safety Actions
A spokesperson for the messaging service stated it regularly monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Medical Expert Cautions
“People are administering substances they cannot confirm. Even if the research behind this drug is valid, these online products may not contain what they advertise,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.
A medical professional of Asda Online Doctor linked the surge in demand to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.
Her staff has previously encountered patients injured by self-injection from unverified sources. “We recognize the disappointment, but buying from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These substances could be contaminated or incorrectly dosed.”
Producer Position
A representative from Eli Lilly said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Therefore at this time no one can market [it] for human use,” they said, noting that any item “falsely representing itself as a company experimental product not yet authorized … may expose patients to potentially serious medical dangers”.
